Biotech Values

[DewDiligence]

Re: ADXS’ ADXS-HPV in anal cancer

So, the CEO noted patients out past two years of treatment but cited a 3-year recurrence rate? How do you know the disease doesn't typically recur in the third year in this patient population?

The probability of recurrence follows an exponential curve, as one would intuitively expect—i.e. there is no significant spike in the recurrence rate during the third year following treatment.

p.s. The NRG Oncology cooperative likes ADXS’s preliminary anal-cancer data enough to want to conduct a phase-3 trial if NCI provides funding.